{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:00:26Z","timestamp":1791460826083,"version":"4.3.4"},"reference-count":116,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Diffuse large B-cell lymphoma (DLBCL) is the most common and biologically heterogeneous subtype of non-Hodgkin lymphoma. While immunochemotherapy has improved outcomes, survival remains variable due to substantial molecular diversity. In people living with HIV (PLWH), DLBCL is the predominant lymphoma subtype and demonstrates more aggressive clinical behaviour, characterised by advanced-stage disease, extranodal involvement, and a potentially poorer prognosis despite antiretroviral therapy. Clarifying differences in the pathogenesis of HIV-associated and HIV-unrelated DLBCL is essential for informing precision therapies. This narrative review highlights the contrasting pathogenic mechanisms, with an emphasis on the interplay between viral oncogenesis, host immunity, and molecular alterations in HIV-associated DLBCL versus DLBCL in immunocompetent individuals. Understanding these differences is critical for refining diagnostic approaches, improving risk stratification, and identifying novel therapeutic strategies tailored to both groups.<\/jats:p>","DOI":"10.3390\/diagnostics16193242","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:26:53Z","timestamp":1791458813000},"page":"3242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Divergent Pathogenesis to Precision Medicine: The Road to Targeted Therapy in HIV-Associated and HIV-Unrelated Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-6608","authenticated-orcid":false,"given":"Stephanie","family":"Murugan","sequence":"first","affiliation":[{"name":"School of Laboratory Medicine and Health Sciences, University of KwaZulu Natal, Private Bag 7, Congella, Durban 4013, South Africa"},{"name":"National Health Laboratory Service (NHLS), Department of Haematology, KwaZulu-Natal Academic Complex, Inkosi Albert Luthuli Hospital, Private Bag X03, Mayville, Durban 4058, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5489-8392","authenticated-orcid":false,"given":"Zivanai Cuthbert","family":"Chapanduka","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Health Sciences, University of Stellenbosch, Private Bag X1, Stellenbosch 7599, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7700-6078","authenticated-orcid":false,"given":"Nadine","family":"Rapiti","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Health Sciences, University of KwaZulu Natal, Private Bag 7, Congella, Durban 4013, South Africa"},{"name":"National Health Laboratory Service (NHLS), Department of Haematology, KwaZulu-Natal Academic Complex, Inkosi Albert Luthuli Hospital, Private Bag X03, Mayville, Durban 4058, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.ccell.2023.09.004","article-title":"Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial","volume":"41","author":"Zhang","year":"2023","journal-title":"Cancer Cell"},{"key":"ref_5","unstructured":"UNAIDS (2024, February 21). Global HIV & AIDS Statistics-Fact Sheet. [Updated 2023]. Available online: https:\/\/thepath.unaids.org\/wp-content\/themes\/unaids2023."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000456036","article-title":"HIV-Associated Malignant Lymphoma","volume":"40","author":"Brunnberg","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_7","first-page":"31","article-title":"HIV\/AIDS Associated Lymphoma: Review","volume":"12","author":"Berhan","year":"2022","journal-title":"Blood Lymphat. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-143253","article-title":"Clinical Features, Treatments and Outcomes of HIV-Associated Diffuse Large B-Cell Lymphoma: A Single-Center Experience","volume":"136","author":"Magnusson","year":"2020","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s43046-022-00131-6","article-title":"Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: A single-center KwaZulu-Natal, South African hospital 12-year retrospective review","volume":"34","author":"Rapiti","year":"2022","journal-title":"J. Egypt. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/QAD.0000000000000624","article-title":"HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era","volume":"29","author":"Baptista","year":"2015","journal-title":"AIDS"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Straista, M., Caccuri, F., Arnaut, N., Caruso, A., and Slevin, M. (2025). Pathological Mechanisms Involved in HIV-Associated Lymphomagenesis: Novel Targeted Therapeutic Approaches. Cells, 14.","DOI":"10.3390\/cells14100705"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Manyau, M.C.P., Zambuko, B., Chatambudza, M., Zhou, D.T., and Manasa, J. (2024). Still Far to Go with Characterisation of Molecular and Genetic Features of Diffuse Large B-Cell Lymphoma in People Living with HIV: A Scoping Review. Oncol. Rev., 18.","DOI":"10.3389\/or.2024.1375291"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1007\/s00277-025-06395-x","article-title":"Outcomes of the transformation to diffuse large B-cell lymphoma in hodgkin lymphoma and indolent B-cell non-Hodgkin lymphoma: A population-based study","volume":"104","author":"Zheng","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and Pathogenesis of Diffuse Large B-cell Lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11912-021-01155-2","article-title":"Molecular Subgroups of Diffuse Large B Cell Lymphoma: Biology and Implications for Clinical Practice","volume":"24","author":"Weber","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hon.3141","article-title":"The germinal center in the pathogenesis of B cell lymphomas","volume":"41","author":"Pasqualucci","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Stebegg, M., Kumar, S.D., Silva-Cayetano, A., Fonseca, V.R., Linterman, M.A., and Graca, L. (2018). Regulation of the Germinal Center Response. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02469"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"qzae015","DOI":"10.1093\/gpbjnl\/qzae015","article-title":"Aberrant Somatic Hypermutation at Super-enhancer Drives B Cell Lymphoma Transformation","volume":"22","author":"Han","year":"2024","journal-title":"Genom. Proteom. Bioinform."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/PAS.0000000000002258","article-title":"Characteristics and Clinical Value of MYC, BCL2, and BCL6 Rearrangement Detected by Next-generation Sequencing in DLBCL","volume":"48","author":"Zeng","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41571-019-0225-1","article-title":"Genetic alterations and their clinical implications in DLBCL","volume":"16","author":"Miao","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/cei.12702","article-title":"Transcription factors regulating B cell fate in the germinal centre","volume":"183","author":"Recaldin","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"ref_24","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., and Theile, J. (2017). WHO Classification of Tumours of Haematopoeitic and Lymphoid Tissues, International Agency for Research on Cancer. [4th ed.]."},{"key":"ref_25","unstructured":"WHO Classification of Tumours Editorial Board (2024). Haematolymphoid Tumours, International Agency for Research on Cancer. [5th ed.]. Available online: https:\/\/publications.iarc.who.int\/637."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12672-025-01958-w","article-title":"Diffuse large B cell lymphoma (DLBCL): Epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: Narrative review","volume":"16","author":"Berhan","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","article-title":"Diffuse large B-cell lymphoma-treatment approaches in the molecular era","volume":"11","author":"Roschewski","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.pathol.2020.02.007","article-title":"Diffuse large B-cell lymphoma in a South African cohort with a high HIV prevalence: An analysis by cell-of-origin, Epstein-Barr virus infection and survival","volume":"52","author":"Cassim","year":"2020","journal-title":"Pathology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1073\/pnas.0804295105","article-title":"Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways","volume":"105","author":"Lenz","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100988","DOI":"10.1016\/j.blre.2022.100988","article-title":"Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas","volume":"56","author":"Morschhauser","year":"2022","journal-title":"Blood Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.neo.2018.03.002","article-title":"Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma","volume":"20","author":"Wang","year":"2018","journal-title":"Neoplasia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12420","DOI":"10.1073\/pnas.1305656110","article-title":"PTEN loss defines a PI3K\/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma","volume":"110","author":"Pfeifer","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","first-page":"3760","article-title":"Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype","volume":"5","author":"Boehringer","year":"2021","journal-title":"Blood Adv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1053\/j.seminhematol.2015.01.008","article-title":"B-cell receptor signaling in diffuse large B-cell lymphoma","volume":"52","author":"Young","year":"2015","journal-title":"Semin. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2024-204704","article-title":"Oncogenic CARD11 Mutations and Autonomous BCR Signaling Act As Functionally Equivalent Alternative Drivers in ABC-DLBCL","volume":"144","author":"Eken","year":"2024","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8483","DOI":"10.1007\/s00432-023-04714-1","article-title":"MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma","volume":"149","author":"Qin","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1182\/blood.V126.23.5051.5051","article-title":"MYD88 L265P Mutation Is a Possible Unfavorable Prognostic Factor in Patients with Diffuse B-Cell Lymphoma","volume":"126","author":"Sidorova","year":"2015","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Cen, H., Tan, X., and Guo, B. (2015). A20 Mutation Is Not a Prognostic Marker for Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0145037"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/leu.2016.243","article-title":"Loss of PRDM1\/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma","volume":"31","author":"Xia","year":"2017","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.immuni.2019.08.006","article-title":"Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma","volume":"51","author":"Meyer","year":"2019","journal-title":"Immunity"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: How deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Hatzi","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1182\/blood-2002-11-3387","article-title":"Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma","volume":"101","author":"Pasqualucci","year":"2003","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ni.2688","article-title":"MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphoma","volume":"14","author":"Ying","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2015-11-684357","article-title":"FBXO11 inactivation leads to abnormal germinal-center formation and lymphoproliferative disease","volume":"128","author":"Schneider","year":"2016","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2013-01-479865","article-title":"Analysis of FOXO1 mutations in diffuse large B-cell lymphoma","volume":"121","author":"Trinh","year":"2013","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Morando, N., Rosenzvit, M.C., Pando, M.A., and Allmer, J. (2024). The Role of MicroRNAs in HIV Infection. Genes, 15.","DOI":"10.3390\/genes15050574"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Plan\u00e8s, R., and Bahraoui, E. (2013). HIV-1 Tat protein induces the production of IDO in human monocyte derived-dendritic cells through a direct mechanism: Effect on T cells proliferation. PLoS ONE, 8.","DOI":"10.1371\/annotation\/d333f74d-496e-48e7-ac30-6dcfdbd7a25b"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Leal, F.E., Premeaux, T.A., Abdel-Mohsen, M., and Ndhlovu, L.C. (2017). Role of Natural Killer Cells in HIV-Associated Malignancies. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.00315"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Epeldegui, M., Thapa, D.R., De la Cruz, J., Kitchen, S., Zack, J.A., and Mart\u00ednez-Maza, O. (2010). CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011448"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1097\/QAD.0000000000002653","article-title":"Frequent expression of activation-induced cytidine deaminase in diffuse large B-cell lymphoma tissues from persons living with HIV","volume":"34","author":"Shponka","year":"2020","journal-title":"AIDS"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Borhis, G., Trovato, M., Chaoul, N., Ibrahim, H.M., and Richard, Y. (2017). B-Cell-Activating Factor and the B-Cell Compartment in HIV\/SIV Infection. Front. Immunol., 8.","DOI":"10.3389\/fimmu.2017.01338"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Huguet, M., Navarro, J.T., Molt\u00f3, J., Ribera, J.M., and Tapia, G. (2023). Diffuse Large B-Cell Lymphoma in the HIV Setting. Cancers, 15.","DOI":"10.3390\/cancers15123191"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Li, M., Lin, F., Guo, R., Wu, D., Shen, R., Harypursat, V., Chen, Y., and Chen, Y. (2025). HIV-1 matrix protein p17: A key factor in HIV-associated cancers. Front. Virol., 5.","DOI":"10.3389\/fviro.2025.1584507"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/leu.2017.106","article-title":"HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells","volume":"31","author":"Germini","year":"2017","journal-title":"Leukemia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"15678","DOI":"10.1002\/jcp.28219","article-title":"HIV-1 Tat protein induces aberrant activation of AICDA in human B-lymphocytes from peripheral blood","volume":"234","author":"Sall","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13027-020-00320-9","article-title":"HIV Nef enhances the expression of oncogenic c-MYC and activation-induced cytidine deaminase in Burkitt lymphoma cells, promoting genomic instability","volume":"15","author":"Mdletshe","year":"2020","journal-title":"Infect. Agents Cancer"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/bmm.15.13","article-title":"The role of the tumor microenvironment in HIV-associated lymphomas","volume":"9","author":"Taylor","year":"2015","journal-title":"Biomark. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/cvr\/cvq045","article-title":"Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling","volume":"86","author":"Rey","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12308-008-0002-z","article-title":"HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas","volume":"1","author":"Nyagol","year":"2008","journal-title":"J. Hematop."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1128\/MCB.24.12.5223-5234.2004","article-title":"Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha","volume":"24","author":"Wakisaka","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/bjc.2015.301","article-title":"The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma","volume":"113","author":"Venturelli","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/his.14798","article-title":"Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: Diagnostic and prognostic implications","volume":"81","author":"Baptista","year":"2022","journal-title":"Histopathology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1182\/blood-2024-206279","article-title":"HIV-Associated Diffuse Large B-Cell Lymphoma Shows Different Genomic Patterns between EBV-Positive and EBV-Negative Tumors","volume":"144","author":"Song","year":"2024","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-14-2083","article-title":"A comparative study of molecular characteristics of diffuse large B-cell lymphoma from patients with and without human immunodeficiency virus infection","volume":"21","author":"Chao","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1182\/blood-2023-182618","article-title":"High Frequency Mutant Genes and Prognosis Value of HIV-Related Diffuse Large B-Cell Lymphoma","volume":"142","author":"Peng","year":"2023","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/bjh.17708","article-title":"EBV-positive HIV-associated diffuse large B cell lymphomas are characterized by JAK\/STAT (STAT3) pathway mutations and unique clinicopathologic features","volume":"194","author":"Chapman","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1073\/pnas.96.17.9809","article-title":"TCL1 oncogene expression in AIDS-related lymphomas and lymphoid tissues","volume":"96","author":"Teitell","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","first-page":"229","article-title":"Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL","volume":"66","author":"Thapa","year":"2014","journal-title":"Am. J. Ther."},{"key":"ref_72","first-page":"143","article-title":"MicroRNA 21 Expression Levels in HIV Negative and HIV Positive Diffuse Large B Cell Lymphoma","volume":"4","author":"Phillips","year":"2015","journal-title":"Hered. Genet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2009.07943.x","article-title":"Genome wide DNA-profiling of HIV-related B-cell lymphomas","volume":"148","author":"Capello","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_74","first-page":"221","article-title":"The single-cell immune landscape of HIV-associated aggressive B-cell lymphoma","volume":"5","author":"Zhang","year":"2025","journal-title":"J. Natl. Cancer Cent."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Chadburn, A., Hernandez, M.M., Dai, J., Harrison, M., Reinoso-Vizcaino, N.M., Barry, A.P., Hocke, E., Abramson, K., Jain, V., and Chan, C. (2025). HIV-associated non-Hodgkin lymphoma tumor-microenvironment axes differ by EBV status across cellular origins. bioRxiv.","DOI":"10.1101\/2025.10.15.682084"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5320","DOI":"10.1182\/blood-2025-5320","article-title":"Distinct genomic landscape & response dynamics of HIV-associated lymphomas identified by integrated noninvasive host and virome profiling","volume":"146","author":"Shi","year":"2025","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"24599","DOI":"10.1038\/s41598-025-10529-6","article-title":"Shared genomic features of HIV+\u2009diffuse large B-cell lymphoma in two African cohorts","volume":"15","author":"Roush","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): A randomised, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Jin, J., Ji, D., Xia, Z., Xue, K., Zhang, Q., Liu, Y., Cao, J., Hong, X., Gu, J.J., and Guo, Y. (2022). Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET\/CT: An analysis of a prospective trial. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09486-4"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1080\/10428194.2025.2525982","article-title":"Ibrutinib added to standard conditioning and as maintenance therapy following autologous hematopoietic stem cell transplantation for relapsed or refractory activated-B-cell type Diffuse Large B-cell lymphoma: Primary analysis of the US intergroup double-blind randomized phase III study Alliance A051301\/BMT-CTN 1201","volume":"66","author":"Andreadis","year":"2025","journal-title":"Leuk. Lymphoma"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1200\/JCO.2006.09.3146","article-title":"Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"25","author":"Robertson","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/j.clml.2018.05.022","article-title":"An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma","volume":"18","author":"Burke","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ejca.2015.10.005","article-title":"A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)","volume":"54","author":"Flinn","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A Phase 2\/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator\u2019s Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.13945","article-title":"Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 1b study from GELTAMO group","volume":"173","author":"Redondo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s10238-022-00920-2","article-title":"Efficacy and safety of lenalidomide in diffuse large B-cell lymphoma: A meta-analysis of randomized controlled trials","volume":"23","author":"Liu","year":"2023","journal-title":"Clin. Exp. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjh.17792","article-title":"Idelalisib in relapsed\/refractory diffuse large B-cell lymphoma: Results from a Nordic Lymphoma Group phase II trial","volume":"196","author":"Ekberg","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V120.21.3663.3663","article-title":"Clinical safety and activity in a Phase 1 trial of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-\u03b4, \u03b3, in patients with advanced hematologic malignancies","volume":"120","author":"Flinn","year":"2012","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","article-title":"Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma","volume":"34","author":"Lenz","year":"2020","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41375-024-02401-9","article-title":"Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma","volume":"38","author":"Willis","year":"2024","journal-title":"Leukemia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2024-198624","article-title":"Final Analysis of the Safety and Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double\/Triple Hit Lymphoma","volume":"144","author":"Diefenbach","year":"2024","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"103157","DOI":"10.1016\/j.eclinm.2025.103157","article-title":"Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: Results of the EpiRCHOP phase II study of the LYSA","volume":"82","author":"Sarkozy","year":"2025","journal-title":"eClinicalMedicine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.21037\/atm-21-6019","article-title":"Safety of chidamide plus rituximab in elderly patients with relapsed or refractory B-cell lymphoma in China: A multicenter, single-arm, phase II study","volume":"9","author":"Chen","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13148-023-01452-6","article-title":"Clinical advances in epigenetic therapies for lymphoma","volume":"15","author":"Rosenthal","year":"2023","journal-title":"Clin. Epigenet."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Li, Y., Zhang, Y., Zhu, C., Han, Y., Gao, X., Yue, J., and Wang, Y. (2026). Novel immunotherapeutic strategies for diffuse large B-cell lymphoma: A comprehensive review. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1704254"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","article-title":"Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B-cell non-Hodgkin lymphoma","volume":"61","author":"Coyle","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-99-118344","article-title":"Mosunetuzumab, a Full-Length Bispecific CD20\/CD3 Antibody, Displays Clinical Activity in Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study","volume":"132","author":"Budde","year":"2018","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: Survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/hiv.13514","article-title":"Enabling CAR T-cell therapies for HIV-positive lymphoma patients\u2014A call for action","volume":"24","author":"Hattenhauer","year":"2023","journal-title":"HIV Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.1002\/hem3.150","article-title":"Human immunodeficiency virus-associated Lymphomas: EHA\u2013ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"8","author":"Bower","year":"2024","journal-title":"HemaSphere"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"20503121251374954","DOI":"10.1177\/20503121251374954","article-title":"Chimeric antigen receptor T-cell therapy and bispecific antibodies in the treatment of lymphoma for human immunodeficiency virus-infected patients: A systematic review","volume":"13","author":"Plasencia","year":"2025","journal-title":"SAGE Open Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"O\u2019Reilly, R.J., Prockop, S., and Oved, J.H. (2024). Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1290059"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s44313-024-00042-6","article-title":"PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: A retrospective analysis","volume":"59","author":"Li","year":"2024","journal-title":"Blood Res."},{"key":"ref_116","first-page":"100268","article-title":"CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leuk. Res. Rep."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/19\/3242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:38:33Z","timestamp":1791459513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/19\/3242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":116,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["diagnostics16193242"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16193242","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}